Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus
Introduction Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated with severe clinical outcomes. MicroRNA (miR)-210 has been reported to be related to T2DM and lipid metabolism. This study aimed to determine whether miR-210 can predict the effects of glimepirid...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2023-02-01
|
| Series: | Archives of Medical Science |
| Subjects: | |
| Online Access: | https://www.archivesofmedicalscience.com/Comparison-of-glimepiride-and-linagliptin-in-the-treatment-of-non-alcoholic-hepatic,161228,0,2.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584844233670656 |
|---|---|
| author | Feng Tian Yali Guo Liping Zhou Qunying Yao Xiaoyan Liang Jiaxin Lu Aiping He Jie Shen |
| author_facet | Feng Tian Yali Guo Liping Zhou Qunying Yao Xiaoyan Liang Jiaxin Lu Aiping He Jie Shen |
| author_sort | Feng Tian |
| collection | DOAJ |
| description | Introduction
Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated with severe clinical outcomes. MicroRNA (miR)-210 has been reported to be related to T2DM and lipid metabolism. This study aimed to determine whether miR-210 can predict the effects of glimepiride and linagliptin on NAFLD with T2DM.
Material and methods
A total of 86 patients with NAFLD with T2DM were randomly categorized into two groups and treated with either linagliptin (5 mg/daily) or glimepiride (2 mg/daily) for 6 months. Furthermore, real-time quantitative polymerase chain reaction was used to evaluate the expression level of miR-210 in the patients’ serum.
Results
Compared with glimepiride, linagliptin was able to significantly reduce the fasting blood glucose level (p = 0.039). Moreover, the expression level of miR-210 was positively correlated with fasting blood glucose level (r = 0.272, p = 0.011) and 2 h post-breakfast blood glucose level (r = 0.245, p = 0.023). The fasting insulin level was negatively correlated with the expression level of miR-210 (r = –0.224, p = 0.038). Also, the alanine transaminase (ALT) level (r = 0.438, p < 0.001) and ALT/aspartate aminotransferase ratio (r = 0.382, p < 0.001) were positively correlated with miR-210 expression.
Conclusions
Linagliptin was not significantly different from glimepiride in improving the hepatic and renal functions and in reducing the blood lipid level. miR-210 expression was linked to blood glucose and lipid levels and hepatic function, which indicates its role as a prognostic biomarker in the treatment of NAFLD with T2DM using linagliptin and glimepiride. |
| format | Article |
| id | doaj-art-18a1fd709bb64fe88fc26791bcefadb5 |
| institution | Kabale University |
| issn | 1734-1922 1896-9151 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Archives of Medical Science |
| spelling | doaj-art-18a1fd709bb64fe88fc26791bcefadb52025-01-27T10:44:30ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512023-02-012051407141510.5114/aoms/161228161228Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitusFeng Tian0Yali Guo1Liping Zhou2Qunying Yao3Xiaoyan Liang4Jiaxin Lu5Aiping He6Jie Shen7Health Management Division, Shunde Hospital, Southern Medical University, The First People’s Hospital of Shunde, Foshan, ChinaDepartment of Endocrinology, University of Chinese Academy of Sciences Shenzhen Hospital, Shenzhen, ChinaHealth Management Division, Shunde Hospital, Southern Medical University, The First People’s Hospital of Shunde, Foshan, ChinaDepartment of Endocrinology, University of Chinese Academy of Sciences Shenzhen Hospital, Shenzhen, ChinaHealth Management Division, Shunde Hospital, Southern Medical University, The First People’s Hospital of Shunde, Foshan, ChinaHealth Management Division, Shunde Hospital, Southern Medical University, The First People’s Hospital of Shunde, Foshan, ChinaDepartment of Endocrinology, University of Chinese Academy of Sciences Shenzhen Hospital, Shenzhen, ChinaDepartment of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University, The First People’s Hospital of Shunde, Foshan, ChinaIntroduction Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated with severe clinical outcomes. MicroRNA (miR)-210 has been reported to be related to T2DM and lipid metabolism. This study aimed to determine whether miR-210 can predict the effects of glimepiride and linagliptin on NAFLD with T2DM. Material and methods A total of 86 patients with NAFLD with T2DM were randomly categorized into two groups and treated with either linagliptin (5 mg/daily) or glimepiride (2 mg/daily) for 6 months. Furthermore, real-time quantitative polymerase chain reaction was used to evaluate the expression level of miR-210 in the patients’ serum. Results Compared with glimepiride, linagliptin was able to significantly reduce the fasting blood glucose level (p = 0.039). Moreover, the expression level of miR-210 was positively correlated with fasting blood glucose level (r = 0.272, p = 0.011) and 2 h post-breakfast blood glucose level (r = 0.245, p = 0.023). The fasting insulin level was negatively correlated with the expression level of miR-210 (r = –0.224, p = 0.038). Also, the alanine transaminase (ALT) level (r = 0.438, p < 0.001) and ALT/aspartate aminotransferase ratio (r = 0.382, p < 0.001) were positively correlated with miR-210 expression. Conclusions Linagliptin was not significantly different from glimepiride in improving the hepatic and renal functions and in reducing the blood lipid level. miR-210 expression was linked to blood glucose and lipid levels and hepatic function, which indicates its role as a prognostic biomarker in the treatment of NAFLD with T2DM using linagliptin and glimepiride.https://www.archivesofmedicalscience.com/Comparison-of-glimepiride-and-linagliptin-in-the-treatment-of-non-alcoholic-hepatic,161228,0,2.htmllinagliptinglimepiridetype 2 diabetes mellitusnon-alcoholic fatty hepatic diseasemirna-210 |
| spellingShingle | Feng Tian Yali Guo Liping Zhou Qunying Yao Xiaoyan Liang Jiaxin Lu Aiping He Jie Shen Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus Archives of Medical Science linagliptin glimepiride type 2 diabetes mellitus non-alcoholic fatty hepatic disease mirna-210 |
| title | Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus |
| title_full | Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus |
| title_fullStr | Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus |
| title_full_unstemmed | Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus |
| title_short | Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus |
| title_sort | comparison of glimepiride and linagliptin in the treatment of non alcoholic hepatic disease with type 2 diabetes mellitus |
| topic | linagliptin glimepiride type 2 diabetes mellitus non-alcoholic fatty hepatic disease mirna-210 |
| url | https://www.archivesofmedicalscience.com/Comparison-of-glimepiride-and-linagliptin-in-the-treatment-of-non-alcoholic-hepatic,161228,0,2.html |
| work_keys_str_mv | AT fengtian comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT yaliguo comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT lipingzhou comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT qunyingyao comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT xiaoyanliang comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT jiaxinlu comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT aipinghe comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus AT jieshen comparisonofglimepirideandlinagliptininthetreatmentofnonalcoholichepaticdiseasewithtype2diabetesmellitus |